Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of chronic obstructive pulmonary disease~2. Smoking history of more than 10-pack years~Exclusion criteria:~1. History of asthma, allergic rhinitis, myocardial infarction or unstable of life-threatening cardiac arrhythmias~2. Marked baseline prolongation of QT/QTc interval

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- olodaterol 2 mcg (Type: EXPERIMENTAL): solution for inhalation
- olodaterol 5 mcg (Type: EXPERIMENTAL): solution for inhalation
- olodaterol 10 mcg (Type: EXPERIMENTAL): solution for inhalation
- olodaterol 20 mcg (Type: EXPERIMENTAL): solution for inhalation
- olodaterol 40 mcg (Type: EXPERIMENTAL): solution for inhalation
- placebo (Type: PLACEBO_COMPARATOR): solution for inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).